End-of-Phase 2A Meetings
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 18, 2009
May 1, 2020
05202b67-ba5f-49de-b49a-1f5466adf224
Related Documents
Individual Product Bioequivalence Recommendations for Specific Products
Guidance DocumentJune 10, 2010Center for Drug Evaluation and Research
Residual Solvents in Drug Products Marketed in the United States: Guidance for Industry
Guidance DocumentNovember 25, 2009Center for Drug Evaluation and Research
Time and Extent Applications for Nonprescription Drug Products
Guidance DocumentSeptember 29, 2011Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.